期刊文献+

医学论文中有关实验动物描述的要求

原文传递
导出
摘要 在医学论文的描述中,凡涉及实验动物者,在描述中应符合以下要求:(1)品种、口系描述清楚,(2)强调来源,(3)遗传背景,(4)微生物学质量,(5)明确体重,(6)明确等级,(7)明确饲养环境和实验环境,(8)明确性别,(9)有无质量合格证,(10)有对饲养的描述(如饲料类型、营养水平、照明方式、温度、湿度要求),(11)所有动物数量准确,(1:2)详细描述动物的健康状况,(13)对动物实验的处理方式有单独清楚的交代,(14)全部有对照,部分可采用双因素方差分析。
出处 《肿瘤研究与临床》 CAS 2011年第2期76-76,共1页 Cancer Research and Clinic
  • 相关文献

参考文献15

  • 1Metastatic breast cancer. Recommendations proposal from the Euro pean School of Ontology (ESO)-MBC Task Force. Breast, 2007, 16: 9-10.
  • 2Pagani O, Senkus E, Wood W, et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer inst, 2010, 102: 456-463.
  • 3NCCN Breast Cancer Practice Guidlines in Oncology.v.2.2010.
  • 4Groheux D, Moretti JL, Giacchetti S, et al. PET/CT in breast cancer: an update. Bull Cancer, 2009, 96: 1053-1070.
  • 5Lavayssiere R, Cab 6e AE, Filmont JE. Positron Emission TomogTaphy (PET) and breast cancer in clinical practice. Eur J Radiol, 2009, 69: 50-58.
  • 6闫敏,宋三泰,江泽飞,刘晓晴,李彦博,徐建明,刘芳,申戈,孙君重.乳腺癌骨转移的临床病程[J].中国骨肿瘤骨病,2003,2(4):221-224. 被引量:30
  • 7Hammond ME, Hayes DF, Dowsett M, clinical oncology/college of american recommendations for et al. American society of pathologists guideline testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol, 2010, 28: 2784-2795.
  • 8吴世凯,宋三泰.乳腺癌内科治疗新进展[J].中国实用内科杂志,2007,27(24):1901-1903. 被引量:3
  • 9吴世凯,宋三泰.乳腺癌内分泌治疗的新概念[J].中国实用外科杂志,2006,26(4):256-258. 被引量:6
  • 10宋三泰.乳癌内分泌治疗应该注意的几个问题[J].中国实用外科杂志,1997,17(2):70-72. 被引量:6

二级参考文献35

  • 1宋三泰,吴世凯.芳香化酶抑制剂治疗乳腺癌应注意的几个问题[J].肿瘤研究与临床,2005,17(6):361-363. 被引量:6
  • 2宋三泰 汤仲明 等.乳癌组织取样、保存及测定方法对ER测定量的影响及其意义[J].中华肿瘤杂志,1985,7:351-353.
  • 3[1]Martin TJ, Moseley JM. Mechanisms in the skeletal complications of breast cancer. Endocr Relat Cancer., 2000,7: 271 - 284.
  • 4[2]Huber S, Ulsperger E, Gomar C, et al. Osseous metastases in breast cancer:radiographic monitoring of therapeutic response. Anticancer Res,2002,22:1279 - 1288.
  • 5[7]Solomayer EF, Diel IJ, Meyberg GC, et al. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis.Breast Cancer Res Treat, 2000,59: 271 - 278.
  • 6[8]Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer, 2002,2: 584 - 593.
  • 7[1]DOWSETT M.Origin and characteristics of adverse events in aromatase inhibition therapy for breast cancer[J].Seminars in Oncology,2003,30(4):58-69.
  • 8[2]BRUEGGEMEIER RW.Aromatase inhibitors[J].Mechanisms of steroidal inhibitors.Breast cancer Res Treat,1994,30:31-42.
  • 9[3]VAN DEN BOSSCHE HV,MOEREELS H,KOYMANS LM.Aromatase inhibitors-Mechanisms of non-steroidal inhibitors[J].Breast cancer Res Treat,1994,30:43-55.
  • 10[4]JONES S,VOGEL C,ARKHIPOV A,et al.Multiple,phase Ⅱ trail of exemestane as third-line hormonal theapy of postmenopausal women with metastatc breast cancer.Aromasin Study Group[J].J Clin Oncol,1999,17:3418-3425.

共引文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部